Results of the feasibility study of clinical trials of the new cancer treatment technology Karanahan for patients with advanced breast cancer

Multi-year research into the synergistic effect of cyclophosphamide (CP) and complex composite double-stranded DNA preparation (DNAmix) has made it possible to develop the novel Karanahan technology for treating malignant tumors. After being applied, the technology results in eradication of cancer stem cells, induction of extensive apoptosis of committed cancer cells, and destruction of suppressor activity of tumor-associated stroma. The therapeutic efficacy of the Karanahan cancer treatment technology is independent of both tumor immunogenicity and the patient’s immune status. Breast cancer is the most common human malignancy; its treatment remains extremely challenging in current clinical practice. It is suggested that in patients with advanced breast cancer, the Karanahan technology will ensure therapeutic eradication of cancer stem cells, substantially slowing down disease progression and extending the survival of palliative patients. The objective of this clinical trial is to examine the feasibility and practical applicability of the Karanahan technology in clinical practice for patients with advanced breast cancer and identify critical elements of the technology when transferred from animal models to humans.